Azitra (AZTR) Cash from Investing Activities (2022 - 2026)
Azitra (AZTR) reported Cash from Investing Activities of -$37139.0 for Q1 2026, down 71.26% on a YoY basis from -$129214.9 in Q1 2025, and up 55.71% quarter-over-quarter from -$83858.0 in Q4 2025.
Azitra (AZTR) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Azitra has reported Cash from Investing Activities for 5 years, with the latest figure at -$37139.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 71.26% year-over-year to -$37139.0; the trailing twelve-month figure through Mar 2026 stood at -$198362.0 (up 37.98% YoY), and the FY2025 full-year result was -$182909.0, up 51.77% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$37139.0, up from -$83858.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$21686.0 in Q1 2025, with the low at -$115532.0 in Q4 2024.
- Historically, Cash from Investing Activities has averaged -$70098.7 across 5 years, with a median of -$79304.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 158.87% — and 2025, when it surged 73.25%.
- Azitra's Cash from Investing Activities stood at -$96791.0 in 2022, then soared by 38.03% to -$59985.0 in 2023, then tumbled by 92.6% to -$115532.0 in 2024, then increased by 27.42% to -$83858.0 in 2025, then soared by 55.71% to -$37139.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$37139.0 (Q1 2026), -$83858.0 (Q4 2025), and -$41078.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | -37,139.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37,139.00 |
| Mar 31, 2026 | -37,139.00 |
| Dec 31, 2025 | -83,858.00 |
| Dec 31, 2025 | -83,858.00 |
| Sep 30, 2025 | -41,078.00 |
| Sep 30, 2025 | -41,078.00 |
| Jun 30, 2025 | -36,287.00 |
| Jun 30, 2025 | -36,287.00 |
| Mar 31, 2025 | -21,686.00 |
| Mar 31, 2025 | -21,686.00 |
| Dec 31, 2024 | -115,532.00 |
| Dec 31, 2024 | -115,532.00 |
| Sep 30, 2024 | -107,888.00 |
| Sep 30, 2024 | -107,888.00 |
| Jun 30, 2024 | -74,748.00 |
| Jun 30, 2024 | -74,748.00 |
| Mar 31, 2024 | -81,078.00 |
| Mar 31, 2024 | -81,078.00 |
| Dec 31, 2023 | -59,985.00 |
| Dec 31, 2023 | -59,985.00 |